An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients with Advanced Solid Malignancies

Study identifier:D5330C00014

ClinicalTrials.gov identifier:NCT05469919

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase 1, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Ceralasertib Administered to Japanese Patients with Advanced Solid Malignancies

Medical condition

Advanced solid malignancies

Phase

Phase 1

Healthy volunteers

No

Study drug

Ceralasertib

Sex

All

Actual Enrollment

12

Study type

Interventional

Age

18 Years - n/a

Date

Study Start Date: 09 Jun 2022
Primary Completion Date: 17 Aug 2023
Study Completion Date: 12 Mar 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jul 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria